8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report
(Date of earliest event reported) January 2,
2018
MEDITE CANCER DIAGNOSTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
333-143570
|
36-4296006
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
4203 SW 34th St.
|
|
|
Orlando,
FL
|
32811
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 5.02
Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain
Officers
On January 2, 2018, the
Board of Directors (the “Board”) of MEDITE Cancer
Diagnostics, Inc. (the “Company”) held a meeting
whereby the Board accepted the resignation of Susan Weisman, the
Chief Financial officer of the Company, effective January 5. The
Company has entered into a Consulting Agreement with Ms. Weisman to
assist the Company during a transition period. Thereafter the Board
elected Stephen Von Rump, the Company’s Chief Executive
Officer, to serve as interim Chief Financial Officer until a
permanent replacement is found.
On
January 2, 2018, the Board accepted the resignation of Eric
Goehausen from the position of Director of the Company. Thereafter
the Board appointed Gregory Fortunoff to the position of Director
of the Company to serve until his resignation or
removal.
Gregory Fortunoff, Age 48, Director
Gregory
Fortunoff is an experienced manufacturing and financial executive
with over 25 year experience of healthcare investing experience.
Since 2014 through the present, Mr. Fortunoff has been the owner of
Jeftex Corporation and is responsible for overseeing the operations
of this 87 year old textile converter company. From 2009 until
2014, Mr. Fortunoff was the owner of G-2 Trading, LLC before
selling the company in 2014. Mr. Fortunoff managed the daily
operations of this equity trading firm with $100,000,000 in
positions. From 2006 to 2011, Mr. Fortunoff served as a Board
Member of American Medical Alert, Inc., a small cap medical device
and communication company which was ultimately sold at a premium to
a private company. In 1992, Mr. Fortunoff earned a B.A. degree in
Marketing from Syracuse University. Mr. Fortunoff is not currently,
nor has he been an officer or director of any company required to
file reports with the Securities Exchange Commission.
Item
9.01
Financial Statements and Exhibits
|
Exhibit No.
|
Description
|
|
|
Resignation Letter
of Susan Weisman
|
|
|
Resignation Letter
of Eric
Goehausen
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
|
|
|
Date:
January 5, 2018
|
By:
|
/s/ Stephen Von Rump
|
|
|
|
Stephen
Von Rump
|
|
|
|
Chief
Executive Officer
|
